Venous thromboembolism (VTE) is a significant problem in the perioperative period, increasing patient morbidity, mortality, and health care costs. It is also considered the most preventable of the major postoperative complications. Despite widespread adoption of prophylaxis guidelines, it appears that morbidity from the disease has not substantially changed within the past 2 decades. It is becoming clear that current prophylaxis efforts are not sufficient. Using more potent anticoagulants may decrease the incidence of VTE, but increase the risk for bleeding and infection. Much has been learned about the pathophysiology of venous thrombogenesis in recent years. Beyond the “traditional coagulation cascade,” which anticoagulants modulate, there is a growing appreciation for the roles of tissue factor, monocytes, neutrophils, neutrophil extracellular traps, microvesicles, and platelets in thrombus initiation and propagation. These recent studies explain to some degree why aspirin appears to be remarkably effective in preventing thrombus propagation. Endothelial dysfunction, traditionally thought of as a risk factor for arterial thrombosis, plays an important role within the cusps of venous valves, a unique environment where the majority of venous thrombi originate. This suggests a role for newer treatment modalities such as statins. Not all patients have an equal likelihood of experiencing a VTE, even when undergoing high-risk procedures, and better tools are required to accurately predict VTE risk. Only then will we be able to effectively individualize prophylaxis by balancing the risks for VTE against the risks associated with treatment. Given the different cell types and pathways involved in thrombogenesis, it is likely that multimodal treatment regimens will be more effective, enabling the use of lower and safer doses of hemostatic modulating therapies such as anticoagulants, antithrombotics, and antiplatelet medications. (Anesth Analg 2017;125:403–12)
VTE AND SURGERY—THE SCOPE OF THE PROBLEM

The true incidence of VTE is a matter of considerable uncertainty, but VTE may affect up to 25% of in-hospital surgical patients. While major surgery is likely the single most important risk factor for VTE,2 the postoperative risk for VTE varies considerably by surgery type, with the highest incidence reported in hip and knee arthroplasty and cancer surgery.6,17 The reported increase in risk for VTE following surgery compared to spontaneous VTE varies significantly, however, with values ranging from 8- to 70-fold.2,4,17

Estimates of the annual fatal PE events vary from as low as 100,000 to as high as 300,000,6,16,19 and wide estimates of the number of VTE events ranging from 350,000 to 2,000,000 may also be found.6,20,21 The fraction of these associated with surgery and anesthesia is not known precisely, but is estimated to be between 20% and 30%.10

An important reason for this substantial degree of uncertainty is that studies generally report symptomatic DVTs only, even though VTE is predominantly an easily overlooked silent disease.5,10,19,22 In fact, in 70% to 80% of in-hospital deaths due to PE, this diagnosis was not even considered prior to the patient’s death.5 Also, VTE may occur several weeks out following surgery, causing the reported incidence of VTE to increase when patients are followed up for longer periods postoperatively.17 Regardless of the true incidence of VTE, however, morbidity from the disease has not substantially changed within the past 2 decades, and it is increasingly clear that current prophylaxis efforts are not sufficient.6,10,23

HISTOLOGICAL OBSERVATIONS

In contrast to arterial thrombosis, the precise mechanisms leading to VTE are not well understood.20 However, the histological appearance of venous thrombosis throughout the various stages of the disease has been carefully documented and should be accounted for by any proposed model.

Intravascular thrombi are classified into 2 histological types: (1) so-called white clots, which form under conditions of high shear and consist primarily of platelets, and (2) “red clots,” which form under conditions of low shear and contain significant quantities of red blood cells and fibrin.24 Arterial white clots trigger myocardial infarction and stroke, whereas venous red clots are the hallmark of VTE.24 In dissection of red clots at necropsy, certain features are evident.

Thrombi almost always originate within a venous valve pocket or region of reduced flow.18,22,25,26 Consistent with this, the thrombi are most organized and loosely tethered to the venous or valvular endothelium at its origin.19,22,25–27 Within the thrombus, laminations of alternating (fibrin-red blood cell) “red” and (platelet-neutrophil) “white” areas are present.18,22,26 These laminations are known as Lines of Zahn and are always present in propagating thrombi.19,22 More proximally, away from the oldest portion of the thrombus, these white areas consisting of platelets and leukocytes with surrounding fibrin borders become increasingly prevalent and also grow in size. As a result, platelet masses are usually large and numerous in the propagating head, but may be small and less prominent elsewhere.22,26 Red areas appear to play the major role with respect to thrombus origin, whereas white areas play the major role with respect to thrombus propagation. Thrombus growth therefore occurs by mechanisms involving platelets in addition to the coagulation cascade.22,26

In arterial thrombi, platelets make up the core, as well as the cellular components closest to the vessel wall. In contrast to this, fibrin appears to be the substance attaching the thrombus to the vessel wall in venous thrombi, with platelets attaching to fibrin downstream.22,24,26–28 In recent years, studies have demonstrated that the red areas are interspersed not only with fibrin threads but also with neutrophil extracellular traps (NETs), essentially extracellular DNA trabeculae that promote clot stabilization and propagation.5,9 Indeed, fibrin, NETs, and ultralarge von Willebrand factor (ul-vWF) provide the required scaffolding that facilitates thrombus growth.6,8,29

VENOUS THROMBOGENESIS

As noted, the exact mechanisms of DVT formation are not completely understood, but it is important to appreciate and understand a number of critical events in venous thrombogenesis.

Venous Stasis

Normal peripheral venous flow is required to prevent the accumulation of procoagulants such as thrombin, which could overcome local anticoagulant defense mechanisms under conditions of stasis.29 Normal peripheral venous flow is the sum total of 2 complementary components. The first is continuous venous flow, also referred to as laminar or streamline flow,16,27,26,30,31 which occurs in the supine, still individual. This type of flow relies on vis a tergo, the pressure generated by left ventricular contraction and elastic recoil of the arterial tree, which pushes blood through the capillary beds back to the atria.30,31 While vis a tergo acts as the primary driving pressure, streamline venous flow is also affected by changes in microvascular resistance and increases in venous pressure.16,27,29,30 As such, streamline flow is sensitive to sympathetic mediated changes in microvascular tone, and particularly vulnerable to venous obstruction due to positioning or tissue edema, as observed in knee and hip arthroplasty surgery. The second contribution to peripheral venous blood flow occurs during muscle contraction, when the deep veins are compressed to force blood back to the heart. This is known as pulsatile flow, and it is facilitated by venous valves that prevent reflux secondary to gravity (Figure 1). Pulsatile flow is significantly decreased during bed rest and abolished by general anesthesia.

Continuous venous flow helps to maintain the pro- and antithrombotic balance by preventing local accumulation of thrombin, but is insufficient to prevent thrombus formation in the venous valve pockets in the absence of pulsatile flow. Only pulsatile flow is effective in emptying the venous valve pockets where DVTs are known to originate.18,22,26–33 Further, in the absence of pulsatile flow, the parietalis endothelium (Figure 1) of the valve cusp is rendered hypoxic within a matter of 2 hours in spite of normal continuous venous flow,18,27,29,31 a consequence of the cusp’s avascular
Venous Valve Hypoxia and Endothelial Dysfunction

The histological findings described above suggest that DVTs almost always originate in venous sinuses. Interestingly, not all individuals have the same number of venous valves, and the risk for developing DVT increases with an increase in the number of venous valves.\textsuperscript{24,34} Furthermore, compared to regular venous endothelial cells, venous valve endothelial cell surfaces express significantly higher levels of anticoagulant proteins such as thrombomodulin and endothelial cell protein C receptor, and at the same time lower levels of the procoagulant ul-vWF.\textsuperscript{34} Similar to the arterial circulation, it therefore appears that normal endothelial function, in particular in the at-risk venous pockets, may play a pivotal role in preventing thrombosis.\textsuperscript{24,34,36}

Unfortunately, because of the tenuous oxygen supply outlined above, endothelial cells in venous valves are remarkably at risk for hypoxia in the absence of pulsatile flow.\textsuperscript{18,24,27–29,31,34} Hypoxia and subsequent inflammation activate endothelial cells to downregulate the expression of the anticoagulant proteins and upregulate the expression of procoagulant proteins such as tissue factor (TF) and vWF, disrupting the delicate balance between local pro- and anticoagulant mechanisms.\textsuperscript{24,34,36–40} It is important to understand that this endothelial phenotypic change occurs quite rapidly. In fact, within 30 minutes of hypoxia, endothelial Weibel-Palade bodies begin to release ul-vWF, P-selectin, and E-selectin,\textsuperscript{37,39} thereby activating endothelial cells to promote thrombogenesis.

Thrombus Propagation: Platelet and Leukocyte Accumulation

The exact pathophysiology of thrombus propagation remains somewhat uncertain, but likely involves cyclical thrombus organization and influx of fresh venous blood.\textsuperscript{28} The process continues layer by layer as described histologically.\textsuperscript{22,26} (Figure 3), with organization diminishing farther away from the original nidus.\textsuperscript{18,26} The ebb and flow of venous blood into and out of the valve pocket leads to the formation of a striated thrombus, which eventually fills the valve pocket and encroaches on the main venous channel (Figure 4).

As the thrombus enlarges, more ul-vWF and P-selectin are released during platelet activation and degranulation. Degradation of ul-vWF requires exposure of the protein to higher shear rates, which in turn leads to molecular extension and degradation by the enzyme ADAMTS 13.\textsuperscript{29} Therefore, in contrast to initial thrombotic nidus formation, which occurs in the absence of pulsatile flow, thrombus propagation is more likely in the absence of continuous venous flow.
In summary, it is clear that multiple pathways and many different cells types, in addition to the traditional coagulation cascade, interact in a complex manner to promote thrombogenic nidus formation and subsequent thrombus propagation. These mechanisms may offer many new molecular targets for intervention in addition to traditional anticoagulation and perhaps explain why anticoagulation on its own has largely failed to eliminate VTE.

PREDICTING PERIOPERATIVE VTE RISK

While a blanket approach to prophylaxis can be adopted in high-risk surgical procedures, for some patients the risk for bleeding and postoperative infection associated with prophylaxis may outweigh the risk for VTE. Accurate preoperative VTE risk assessment is therefore essential for appropriate prophylaxis selection. However, as described above, accurate outcome data are lacking and risk prediction tools are not precise. Even the massive National Surgical Quality Improvement Program database, which is the basis for one of the risk prediction algorithms, records only symptomatic VTE observed within 30 days of surgery. For these reasons, VTE risk is usually crudely assigned as low, moderate, high, or highest. Swanson points out that the Caprini Score, arguably the most widely used VTE prediction tool, is not always accurate and may overestimate or underestimate the risk of VTE.

Figure 2. Activation of endothelium of valve cusp secondary to hypoxia and/or inflammation. MVs indicates microvesicles; RBC, red blood cell; vWF, von Willebrand factor; NETS, neutrophil extracellular traps. i, valvular hypoxia initiates process; ii, binding of blood elements to endothelium; iii, tissue factor expression; iv, fibrin thread formation and NET scaffolding.
risk prediction tool, has no firm pathophysiologic footing, but rather is based on “logic, emotion, experience, and intuition.” To put the individual risk factors in the Caprini Score in better perspective, Swanson\textsuperscript{51} compared each Caprini risk factor score with published levels of relative risk, as shown in Table 1, and found no correlation. Another recent study of surgical patients came essentially to the same conclusion that use of all but the highest Caprini scores (≥7) led to overmedication of potent pharmacological agents.\textsuperscript{52} Clearly, there is a need for more refined tools to predict perioperative VTE risk.

PREVENTING PERIOPERATIVE VTE

Several guidelines have been published with the goal of preventing VTE. Unfortunately, adoption and adherence to these guidelines still provide a huge opportunity for health care improvement. Implementing strategies to improve compliance should be a primary focus point for all institutions.\textsuperscript{21} Adopting simplified more universal protocols, a strategy to improve compliance, may not serve all patients well though. In the clinical practice of anesthesiology, patient management is routinely individualized, tailored to both patient and surgical factors. Anesthesiologists have an opportunity to make sure each and every patient receives individualized optimum prophylaxis, with the goal to prevent perioperative VTE. Similar to perioperative myocardial infarction, stroke, or kidney injury, anesthesiologists should also be acutely aware of VTE risk factors to individualize patient management within the context of the surgical procedure. This is especially relevant in light of the fact that many, if not most, VTEs begin their germination in the operating room, often at the outset of anesthetic induction.\textsuperscript{32,53,54} Similar to acute and chronic postoperative pain, where several pathways are involved and a multimodal therapeutic approach is required, it is becoming evident that multiple pathways beyond the coagulation cascade are involved in perioperative VTE, and merely relying on anticoagulants is insufficient.\textsuperscript{55}

**Intermittent Pneumatic Compression Devices**

Intermittent pneumatic compression devices (ICDs) should be the cornerstone in VTE prevention.\textsuperscript{10,21,56–60} A recent large meta-analysis concluded that in hospitalized patients ICDs are more effective than thromboembolic deterrent stockings and may in fact be as effective as pharmacological prophylaxis, without the additional risk for bleeding.\textsuperscript{59} Additionally, combining ICDs with pharmacological prophylaxis further...
EFFECT.

Following surgery, there is some uncertainty regarding the effectiveness of ICDs in reducing the incidence of VTE following surgery. This has not been well studied.

Empty radiopaque dye from the venous valve pockets more low (reverse Trendelenburg) position was sufficient positioning of the lower extremities in the nondependent (reverse Trendelenburg) position. This might be accomplished by (i) preinduction and prolonged utilization of portable ICDs, (ii) early ambulation following surgery, and (iii) regularly scheduled foot and calf exercises, at least every 2 hours. Interestingly, in 1960 McLachlin et al noted that intermittent positioning of the lower extremities in the nondependent (reverse Trendelenburg) position was sufficient to empty radiopaque dye from the venous valve pockets more effectively than vigorous calf contractions, a low-risk intervention. This has not been well studied.

Although there is widespread agreement regarding the effectiveness of ICDs in reducing the incidence of VTE following surgery, there is some uncertainty regarding the exact mechanisms by which they achieve this beneficial effect. It has been suggested that ICDs derive their benefits not only from an increase in pulsatile flow, but also from increased fibrinolytic activity. This theory originated with a 1976 Lancet publication by Knight and Dawson, where the incidence of DVT was examined in 111 patients, 53 of whom had ICDs applied to the arms. The occurrence of DVT, as defined by a fibrinogen leg scans, decreased from 32.7% to 13.2% and the expected postsurgical decrease in euglobulin clot lysis time, a measure of fibrinolytic activity, was prevented for 2 days. A considerable number of subsequent studies, however, have failed to demonstrate any enhancement of fibrinolytic activity. We therefore conclude that the prevention of nonpulsatile flow is the primary beneficial action of ICDs.

It is not clear if the type of ICD utilized is important. Maynard advises that only portable, battery-powered ICDs capable of recording and reporting wear time on a daily basis are recommended for inpatient and extended use. Efforts should be made to achieve daily compliance of 18 hours or more. and Zhao et al examined various ICDs for VTE prevention and found no significant difference in effectiveness. Since effectiveness appears to be a result of patient compliance, as well as when use was initiated, convenience may be the most important factor in device selection.

A recent study by Nunley et al with approximately 3000 patients undergoing hip and knee arthroplasties found long-term portable ICD therapy (approximately 10 days) combined with aspirin equal in effectiveness to traditional anticoagulation with warfarin. Colwell et al reported similar findings, again with a cohort of approximately 3000 patients, demonstrating that the effectiveness of long-term portable ICD therapy (minimum of 10 days) for VTE prevention was noninferior to warfarin, rivaroxaban, dabigatran, or enoxaparin. These clinical trials offer a strong argument in favor of long-term ICD usage. They also offer some reassurance that high VTE risk surgical procedures, such as hip and knee arthroplasties, can be safely performed without the use of potent anticoagulants, which may increase the risk for surgical bleeding and prohibit the use of neuraxial anesthetic techniques. To be clear, we are not advising against the use of anticoagulants for VTE prophylaxis, but merely questioning the role of potent anticoagulants as first-line therapy for a flow-induced complication. This is particularly true on the day of surgery when the risk for bleeding complications is at its greatest. In our opinion, mechanical ICD thromboprophylaxis should be routinely administered to all patients at risk for VTE unless contraindicated.

**Aspirin**

As described earlier, immunological, hematological, and histological studies suggest a primary role for the TF-triggered extrinsic clotting cascade and factor VIIa in thrombus initiation within the venous valve cuff. Platelet activation and the intrinsic or contact cascade then assume a major role once propagation and enroachment occur. Therefore, maintenance of pulsatile flow and anticoagulants should play the major role in minimizing thrombus initiation, whereas maintenance of optimal venous flow (as, for example, via goal-directed fluid therapy) and antiplatelet drugs should be effective in preventing thrombus propagation.

Increasingly, studies are calling into question the effectiveness of potent anticoagulants as the primary means of VTE prevention in medical and surgical patients. Indeed, it has even been suggested that all-cause mortality may be greater with their use. Compared to anticoagulants, aspirin is believed to be associated with a lower incidence of bleeding and infectious complications, the rationale behind

---

**Table 1. Comparison of Caprini Scores With Relative Risk Factors**

<table>
<thead>
<tr>
<th>Condition</th>
<th>Caprini Score</th>
<th>Relative Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age &gt;75 y</td>
<td>3</td>
<td>9.0</td>
</tr>
<tr>
<td>Postpartum</td>
<td>1</td>
<td>2.0</td>
</tr>
<tr>
<td>Major trauma</td>
<td>5</td>
<td>13.0</td>
</tr>
<tr>
<td>Hospitalization on a medical service</td>
<td>0</td>
<td>8.0</td>
</tr>
<tr>
<td>Cancer</td>
<td>3</td>
<td>6.5</td>
</tr>
<tr>
<td>Surgery</td>
<td>3</td>
<td>6.0</td>
</tr>
<tr>
<td>Pregnancy</td>
<td>1</td>
<td>5.5</td>
</tr>
<tr>
<td>Prolonged bed rest</td>
<td>1</td>
<td>5.5</td>
</tr>
<tr>
<td>Oral contraception</td>
<td>1</td>
<td>4.0</td>
</tr>
<tr>
<td>Factor V Leiden (heterozygous)</td>
<td>3</td>
<td>4.0</td>
</tr>
<tr>
<td>Hormone replacement therapy</td>
<td>1</td>
<td>3.0</td>
</tr>
<tr>
<td>Prothrombin 20110G (heterozygous)</td>
<td>3</td>
<td>2.5</td>
</tr>
<tr>
<td>Obesity (BMI &gt;30)</td>
<td>1</td>
<td>2.5</td>
</tr>
<tr>
<td>Family history</td>
<td>3</td>
<td>2.5</td>
</tr>
<tr>
<td>Travel &gt;4 h</td>
<td>0</td>
<td>2.0</td>
</tr>
<tr>
<td>Elevated homocysteine level</td>
<td>3</td>
<td>1.1</td>
</tr>
</tbody>
</table>

Data from Swanson. 

Abbreviation: BMI, body mass index, kg/m².
an increased adoption of aspirin in VTE prophylaxis. At least 5 studies in orthopedic surgery now suggest that aspirin combined with properly applied ICDs is as effective as warfarin or low-molecular-weight heparin.\textsuperscript{56,71-74}

A recently published meta-analysis of data from the PeriOperative Ischemia Evaluation-2 (POISE-2), Pulmonary Embolism Prevention (PEP), and the Antiplatelet Trialists’ Collaboration also showed that aspirin reduces the risk of symptomatic VTE in hospitalized surgical patients by about one-third.\textsuperscript{75} Consistent with the hypothesis that antiplatelet agents should be effective against thrombus propagation, rather than thrombus initiation, exploratory analyses in this study found that aspirin was more effective in preventing large thrombi than smaller thrombi and may decrease the severity of PE.\textsuperscript{75} Interestingly, the authors also reported that combining aspirin with anticoagulant prophylaxis did not modify the effect of aspirin on VTE or bleeding.\textsuperscript{75} Therefore, in contrast to combining mechanical prophylaxis with either anticoagulants or aspirin,\textsuperscript{10,67} the effects of aspirin and anticoagulants may not be additive.

**Novel Oral Anticoagulants**

Novel oral anticoagulants that potently inhibit factor Xa (such as rivaroxaban and apixaban) or thrombin (dabigatran) without the need for blood level monitoring offer an extremely attractive alternative to current anticoagulants in perioperative VTE prophylaxis. A recent meta-analysis on the safety and efficacy of these drugs in preventing VTE after hip and knee arthroplasty showed that these drugs, compared to enoxaparin 40 mg once a day, do indeed lower VTE risk, but at the expense of increased postoperative bleeding.\textsuperscript{76} At the dosing regimens tested, none of the oral agents were more effective than enoxaparin 30 mg twice daily. Predictably, the agents with the highest efficacy in preventing VTE also had the greatest risk for bleeding. The agent with the most favorable risk profile for bleeding was apixaban 2.5 mg twice daily, which appears to be a good alternative to enoxaparin 40 mg once daily.

Perioperative bleeding has associated risks beyond those of blood product transfusion and is far from being an innocuous event. It is important to note that bleeding typically occurs in the postoperative period when it is much more difficult to deal with. Furthermore, a much more sinister consequence of postoperative bleeding is the associated risk for infection, which can be devastating in the presence of prostheses. A recent single-center report of increased deep surgical site infections in patients who received rivaroxaban for thromboprophylaxis following knee or hip arthroplasty surgery is concerning.\textsuperscript{78}

**Statins**

A number of recently published studies observed a significant reduction in VTE risk in patients taking statin drugs.\textsuperscript{8,24,77-79} The mechanism by which this group of drugs prevents VTE is unknown, but Mackman\textsuperscript{24} has suggested their effect is possibly mediated through the inhibition of monocyte TF expression. Statins are also known to potently inhibit vascular inflammation, improve endothelial dysfunction, and prevent thrombogenesis, all of which may play a role in modifying VTE risk.\textsuperscript{77} At this stage, prospective randomized data to suggest routine use of perioperative statins for VTE prophylaxis are still lacking and cannot be recommended, unless required for an alternative indication.

**Lidocaine and Neuraxial Blockade**

Blocking leukocyte and leukocyte-derived MVs binding to activated endothelium, predominantly through P-selectin coupling, may provide another novel method to prevent early venous thrombus formation, a hypothesis supported by several animal studies.\textsuperscript{24} While clinical studies using P-selectin inhibitors are still lacking, a widely used anesthetic technique may be of benefit. Intravenous lidocaine, which is increasingly used as part of multimodal analgesic strategies, has been shown to significantly attenuates increases in plasma P-selectin and platelet-leukocyte aggregates.\textsuperscript{80} The clinical significance of this finding is still unknown, and the effects of intravenous lidocaine on VTE have not been studied.

In contrast to intravenous lidocaine, the benefits of neuraxial anesthesia in preventing VTE are well documented.\textsuperscript{70,71,81-83} Neuraxial anesthesia offers 2 advantages to the patient with respect to VTE: (1) the presence of neuraxial anesthesia prior to incision reduces the stress response and resulting cytokine release, ameliorating the increase in clotting kinetics; and (2) improvement in total venous blood flow.\textsuperscript{81} If maintained into the postoperative period, epidural analgesia may improve washout of thrombin as encroachment occurs.

**PREOPERATIVE GENOMIC PROFILING**

As we enter the era of precision medicine, preoperative genomic profiling will likely improve preoperative risk stratification and hopefully also lead to the development of newer therapeutic interventions. Inherited thrombophilias may be involved in up to 40% of VTE cases.\textsuperscript{1,84} The relative risk associated with these conditions are outlined in Table 2. Unfortunately, unlike what is observed in preventative strategies where combination therapies are at best additive, the risk factors for VTE may enhance VTE risk in a synergistic way.\textsuperscript{24} For example, the risk for VTE in patients on oral contraceptives is increased 4-fold, whereas the risk is increased 7-fold in patients with factor V Leiden deficiency. However, in a factor V Leiden patient on oral contraceptives, the risk is increased 36-fold.\textsuperscript{24,85} Such patients are at risk for unprovoked VTE and could develop perioperative VTE even after minor surgery. Finally, genome-wide association studies have so far been of limited value in identifying further important polymorphisms. It is possible that

<table>
<thead>
<tr>
<th>Table 2. Increased Relative Risk of VTE for Various Thrombophilias</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Genetic Factor</strong></td>
</tr>
<tr>
<td>Factor V Leiden (homozygous)</td>
</tr>
<tr>
<td>Antithrombin deficiency</td>
</tr>
<tr>
<td>Prothrombin G20210A (homozygous)</td>
</tr>
<tr>
<td>Protein C deficiency</td>
</tr>
<tr>
<td>Protein S deficiency</td>
</tr>
<tr>
<td>Factor V Leiden (heterozygous)</td>
</tr>
<tr>
<td>Prothrombin G20210A (heterozygous)</td>
</tr>
<tr>
<td>Non-O blood</td>
</tr>
</tbody>
</table>

Modified from Mannucci and Franchini.\textsuperscript{84} 
Abbreviation: VTE, venous thromboembolism.
CONCLUSIONS

VTE continues to be a serious problem after surgery, resulting in disabling morbidity and death. VTE is perhaps the most preventable of all the major perioperative complications, yet current prophylaxis guidelines have failed to eliminate the problem. This may be due to poor implementation of guidelines, and every effort should be made to increase awareness and provide each patient with optimum evidence-based prophylaxis. However, it is also likely that we are relying too much on anticoagulation as a primary modality for prophylaxis.

In recent years, great strides have been made in delineating the complex pathogenesis of VTE. With an understanding of the pathogenesis in hand, the anesthesiologist is ideally positioned to make a significant contribution in efforts to lower VTE incidence. Anticoagulant prophylaxis does not prevent venous stasis or venous valve endothelial activation. We therefore advocate for mechanical prophylaxis in the form of ICDs in all patients at risk as a first line of defense against thrombotic nidus formation. Anesthetic and analgesic regimens should enable early and aggressive mobilization, and interventions (such as ICDs) should always start prior to the induction of general anesthesia or deep sedation where feasible. Research efforts should be directed at ways anesthetic techniques could attenuate TF and P-selectin release associated with major surgery and examine the impact of such interventions on VTE. Platelet inhibition with aspirin can play an important role in preventing thrombus propagation and decrease PE risk, while associated with less surgical bleeding or infection. And although the jury is still out, evidence is accumulating that statin drugs may provide much needed additional protection against VTE. Finally, preoperative genomic profiling, combined with standard preoperative evaluation, may help guide appropriate perioperative prophylaxis.

ACKNOWLEDGMENTS

The authors express a deep appreciation to Professors Paul Agutter and Ian Silver for their help and encouragement.

DISCLOSURES

Name: Ronald J. Gordon, MD, PhD.
Contribution: This author helped analyze the data and write the manuscript.
Conflicts of Interest: Dr Gordon is a consultant on perioperative genomics for Millennium Health.
Name: Frederick W. Lombard, MBChB, FANZCA.
Contribution: This author helped analyze the data and write the manuscript.
Conflicts of Interest: None.
This manuscript was handled by: Roman M. Snieckus, MD.

REFERENCES

Perioperative Venous Thromboembolism


70. Sharrock NE, Gonzalez Della Valle A, Go G, Lyman S, Salvati EA. Potent anticoagulants are associated with a higher all-cause


